Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT J BUYNAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1508977984
CMS profile
340544
Location
VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,515.77

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,347.91 5
Food and Beverage $167.86 4

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Alnylam Pharmaceuticals Inc. $1,515.77 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT J BUYNAK

NPI 1508977984 · CMS profile ID 340544

Allopathic & Osteopathic Physicians / Internal Medicine

VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1508977984?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $1,515.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alnylam Pharmaceuticals Inc. $24.8008/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090699 CMS
Alnylam Pharmaceuticals Inc. $44.1208/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090541 CMS
Alnylam Pharmaceuticals Inc. $79.6908/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090695 CMS
Alnylam Pharmaceuticals Inc. $170.0008/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090701 CMS
Alnylam Pharmaceuticals Inc. $95.0008/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090705 CMS
Alnylam Pharmaceuticals Inc. $19.2508/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090707 CMS
Alnylam Pharmaceuticals Inc. $251.2508/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090711 CMS
Alnylam Pharmaceuticals Inc. $84.0008/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090713 CMS
Alnylam Pharmaceuticals Inc. $747.6608/12/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926090539 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,627.38 35
PY2022 $1,515.77 9
PY2023 $2,547.31 21
PY2024 $2,804.68 27
PY2025 $2,542.53 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,038,550.53 603
PY2024 Principal investigator $5,031,915.33 601
PY2023 Recipient $906.71 2
PY2023 Principal investigator $4,138,599.32 2,384
PY2022 Recipient $3,104.59 10
PY2022 Principal investigator $5,204,363.35 1,133
PY2021 Principal investigator $3,348,948.64 610
PY2020 Recipient $1,489.26 13
PY2020 Principal investigator $1,938,354.41 292
PY2019 Recipient $658.79 10
PY2019 Principal investigator $1,439,149.33 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

610 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423875
Principal investigator 1 AstraZeneca Pharmaceuticals LP $188.73 12/31/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 826495967
Principal investigator 1 PFIZER INC. $989.55 12/31/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832567207
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,660.00 12/28/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576637
Principal investigator 1 Janssen Pharmaceuticals, Inc $41,205.00 12/28/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576659
Principal investigator 1 Janssen Research & Development, LLC $152,401.00 12/28/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838749
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055343
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055357
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055371
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055385
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055399
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055413
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055423
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055436
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055449
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055477
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055489
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055503
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055517
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055531
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055545
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055557
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055571
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055585
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055599
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055613
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055627
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055641
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055655
Principal investigator 1 Novo Nordisk AS $25.06 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240587
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314057
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314067
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314077
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314087
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314095
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314105
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314115
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314125
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314135
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314145
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314155
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314165
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314175
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314185
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314195
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314205
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314215
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314225
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314235
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314245
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314251
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314261
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780837
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780839
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780841
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780843
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780845
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780847
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780849
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780851
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780853
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780855
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780859
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781007
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781009
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781011
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781013
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781015
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781017
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781019
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781021
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811781023
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823129
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823131
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823133
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823135
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823137
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823143
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823145
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823147
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823149
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823151
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823153
Principal investigator 1 Novo Nordisk AS $22.75 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823155
Principal investigator 1 Novo Nordisk AS $39.83 12/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811824515
Principal investigator 1 Novo Nordisk AS $358.56 12/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240607
Principal investigator 1 Novo Nordisk AS $24.95 12/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811833733
Principal investigator 1 Novo Nordisk AS $7,067.13 12/22/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189809
Principal investigator 1 Novo Nordisk AS $250.00 12/22/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502643
Principal investigator 1 Novo Nordisk AS $3,231.58 12/22/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780857
Principal investigator 1 PFIZER INC. $23,031.04 12/22/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832567197
Principal investigator 1 Kowa Research Institute, Inc. $247.50 12/15/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
K-877-302 No dispute reported 06/30/2026 771714414
Principal investigator 1 ModernaTX, Inc. $66,690.00 12/15/2021 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941931
Principal investigator 1 Janssen Research & Development, LLC $6,720.00 12/08/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838721
Principal investigator 1 PFIZER INC. $7,212.38 12/07/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832566384
Principal investigator 1 Janssen Pharmaceuticals, Inc $882.00 12/06/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576629
Principal investigator 1 Kowa Research Institute, Inc. $1,980.00 12/01/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
K-877-302 No dispute reported 06/30/2026 771714412
Principal investigator 1 Novo Nordisk AS $25.06 12/01/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532153
Principal investigator 1 Novo Nordisk AS $1,869.48 12/01/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811833735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423825
Principal investigator 1 Novo Nordisk AS $6,038.47 11/29/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819025
Principal investigator 1 Novo Nordisk AS $1,947.95 11/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055463
Principal investigator 1 PFIZER INC. $18,334.00 11/23/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832628669
Principal investigator 1 PFIZER INC. $7,600.00 11/23/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832736825
Principal investigator 1 Janssen Pharmaceuticals, Inc $47,530.00 11/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576671
Principal investigator 1 Janssen Research & Development, LLC $1,650.00 11/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838693
Principal investigator 1 ModernaTX, Inc. $104,256.11 11/19/2021 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941933
Principal investigator 1 Novo Nordisk AS $25.06 11/18/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532143
Principal investigator 1 Janssen Research & Development, LLC $132,567.00 11/17/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838737
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189423
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189789
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189799
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502421
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502431
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502441
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818909
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819023
Principal investigator 1 Novo Nordisk AS $40.00 11/17/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849209
Principal investigator 1 PFIZER INC. $6,649.43 11/16/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832805623
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,360.00 11/12/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576649
Principal investigator 1 Janssen Research & Development, LLC $5,445.00 11/12/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838707
Principal investigator 1 PFIZER INC. $4,333.50 11/05/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832628497
Principal investigator 1 PFIZER INC. $6,891.75 11/05/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832896147
Principal investigator 1 Janssen Pharmaceuticals, Inc $882.00 11/03/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576617
Principal investigator 1 ModernaTX, Inc. $155,285.10 11/03/2021 Non-covered Recipient Entity
Velocity Clinical Research, Valparasio
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/29/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423787
Principal investigator 1 Novo Nordisk AS $4,425.22 10/29/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823141
Principal investigator 1 Novo Nordisk AS $1,434.24 10/27/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240597
Principal investigator 1 Kowa Research Institute, Inc. $2,223.90 10/25/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
K-877-302 No dispute reported 06/30/2026 771714410
Principal investigator 1 Novo Nordisk AS $5,560.15 10/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818911
Principal investigator 1 Janssen Pharmaceuticals, Inc $73,945.00 10/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787577065
Principal investigator 1 Janssen Research & Development, LLC $6,720.00 10/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838941
Principal investigator 1 Janssen Research & Development, LLC $17,400.00 10/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838970
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $440.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $0.50 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 10/18/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 828423793
Principal investigator 1 Novo Nordisk AS $11.20 10/15/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788459
Principal investigator 1 Novo Nordisk AS $4.16 10/15/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878403
Principal investigator 1 Novo Nordisk AS $7.91 10/15/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878405
Principal investigator 1 PFIZER INC. $9,593.10 10/08/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832779267
Principal investigator 1 Janssen Research & Development, LLC $10,087.00 10/06/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 10/05/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/05/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 10/05/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 828423753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 10/05/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423789
Principal investigator 1 Novo Nordisk AS $990.00 10/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 833635843
Principal investigator 1 Novo Nordisk AS $330.00 10/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 833635845
Principal investigator 1 Janssen Research & Development, LLC $525.00 10/01/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838663
Principal investigator 1 Janssen Research & Development, LLC $1,620.00 10/01/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423721
Principal investigator 1 Novo Nordisk AS $24.56 09/29/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502371
Principal investigator 1 Novo Nordisk AS $1,510.92 09/29/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532163
Principal investigator 1 Kowa Research Institute, Inc. $4,515.30 09/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771713522
Principal investigator 1 Novo Nordisk AS $6,310.96 09/24/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189433
Principal investigator 1 Novo Nordisk AS $4,068.58 09/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823139
Principal investigator 1 PFIZER INC. $8,672.40 09/23/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832692403
Principal investigator 1 Gilead Sciences, Inc. $762.00 09/22/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 803524475
Principal investigator 1 Janssen Pharmaceuticals, Inc $101,855.00 09/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576165
Principal investigator 1 Janssen Research & Development, LLC $9,481.00 09/22/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838279
Principal investigator 1 ModernaTX, Inc. $4,260.12 09/22/2021 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941999
Principal investigator 1 PFIZER INC. $14,750.00 09/22/2021 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 832628660
Principal investigator 1 Amgen Inc. $275.00 09/20/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 830981949
Principal investigator 1 Janssen Pharmaceuticals, Inc $672.00 09/17/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576177
Principal investigator 1 ModernaTX, Inc. $102,119.06 09/17/2021 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941995
Principal investigator 1 ModernaTX, Inc. $125,027.89 09/17/2021 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941997
Principal investigator 1 Janssen Research & Development, LLC $7,040.00 09/15/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838311
Principal investigator 1 Novo Nordisk AS $350.00 09/10/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811682289
Principal investigator 1 Novo Nordisk AS $14.95 09/10/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811682295
Principal investigator 1 Novo Nordisk AS $1.00 09/10/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895961
Principal investigator 1 Novo Nordisk AS $9.99 09/10/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895963
Principal investigator 1 Janssen Pharmaceuticals, Inc $9,000.00 09/08/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787576239
Principal investigator 1 Novo Nordisk AS $1,980.00 09/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502381
Principal investigator 1 PFIZER INC. $7,399.35 09/04/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832760235
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189143
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502361
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818895
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818897
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849139
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849141
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849143
Principal investigator 1 Novo Nordisk AS $39.90 09/03/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849145
Principal investigator 1 Janssen Pharmaceuticals, Inc $45,875.00 09/01/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423565
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423575
Principal investigator 1 Novo Nordisk AS $2,522.27 08/30/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314047
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,452.00 08/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470171
Principal investigator 1 Janssen Pharmaceuticals, Inc $27,620.00 08/25/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 787575855
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811680753
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811680759
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811680765
Principal investigator 1 Novo Nordisk AS $4.99 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811680771
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811682301
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788439
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788441
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788443
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788445
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788447
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788449
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788451
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788453
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788455
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788457
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788461
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788463
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811788465
Principal investigator 1 Novo Nordisk AS $9,360.93 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849207
Principal investigator 1 Novo Nordisk AS $1,510.92 08/25/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811857721
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878385
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878387
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878389
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878391
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878393
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878395
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878397
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878399
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878401
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878407
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878409
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811878411
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895947
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895949
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895951
Principal investigator 1 Novo Nordisk AS $4.99 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895953
Principal investigator 1 Novo Nordisk AS $650.00 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895955
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895957
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895959
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895965
Principal investigator 1 Novo Nordisk AS $2.65 08/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
EX6018-4758 No dispute reported 06/30/2026 811895967
Principal investigator 1 Kowa Research Institute, Inc. $495.00 08/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771713520
Principal investigator 1 Gilead Sciences, Inc. $1,761.00 08/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 803524473
Principal investigator 1 PFIZER INC. $4,633.20 08/21/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832861705
Principal investigator 1 Janssen Research & Development, LLC $6,720.00 08/20/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838295
Principal investigator 1 Novo Nordisk AS $23.06 08/18/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811857719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50,000.00 08/16/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423907
Principal investigator 1 Novo Nordisk AS $4.95 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189133
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189403
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189413
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189751
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189761
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189769
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189779
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502343
Principal investigator 1 Novo Nordisk AS $4.95 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502351
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502623
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502633
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818891
Principal investigator 1 Novo Nordisk AS $4.95 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818893
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819017
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849131
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849133
Principal investigator 1 Novo Nordisk AS $4.95 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849135
Principal investigator 1 Novo Nordisk AS $4.95 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849137
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849167
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849169
Principal investigator 1 Novo Nordisk AS $38.97 08/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849203
Principal investigator 1 Novo Nordisk AS $23.06 08/13/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811833731
Principal investigator 1 PFIZER INC. $23,727.20 08/06/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832796985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423619
Principal investigator 1 Novo Nordisk AS $5,046.22 07/28/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823125
Principal investigator 1 Novo Nordisk AS $24.56 07/28/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849165
Principal investigator 1 Novo Nordisk AS $4,581.67 07/28/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849205
Principal investigator 1 Novo Nordisk AS $2,247.48 07/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240391
Principal investigator 1 Janssen Research & Development, LLC $8,388.00 07/23/2021 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787838321
Principal investigator 1 Kowa Research Institute, Inc. $2,635.20 07/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771713518
Principal investigator 1 Novo Nordisk AS $23.06 07/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532133
Principal investigator 1 SANOFI PASTEUR INC. $3,420.00 07/23/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838376007
Principal investigator 1 ModernaTX, Inc. $62,938.69 07/21/2021 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941993
Principal investigator 1 Novo Nordisk AS $24.56 07/21/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849163
Principal investigator 1 Novo Nordisk AS $330.00 07/20/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 07/19/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 07/19/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 07/19/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 07/19/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 07/19/2021 Non-covered Recipient Entity
Velocity Clinical Research,Valparaiso
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension No dispute reported 06/30/2026 828423551
Principal investigator 1 PFIZER INC. $8,541.45 07/09/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832749435
Principal investigator 1 Novo Nordisk AS $594.00 07/08/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819015
Principal investigator 1 ModernaTX, Inc. $57,449.84 07/01/2021 Non-covered Recipient Entity
Velocity Clinical Research Valparaiso
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 860941991
Principal investigator 1 Novo Nordisk AS $10,105.40 06/28/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811198783
Principal investigator 1 Novo Nordisk AS $717.12 06/28/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811241737
Principal investigator 1 Novo Nordisk AS $4,554.58 06/28/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314291
Principal investigator 1 Novo Nordisk AS $23.06 06/25/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240381
Principal investigator 1 SANOFI PASTEUR INC. $5,980.00 06/25/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838375909
Principal investigator 1 Gilead Sciences, Inc. $65.00 06/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 803524471
Principal investigator 1 Janssen Research & Development, LLC $64,405.00 06/23/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839881
Principal investigator 1 Kowa Research Institute, Inc. $1,965.60 06/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771711404
Principal investigator 1 PFIZER INC. $2,026.35 06/23/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832699055
Principal investigator 1 SANOFI PASTEUR INC. $27,790.00 06/11/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838375871
Principal investigator 1 PFIZER INC. $1,084.05 06/05/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832751485
Principal investigator 1 PFIZER INC. $2,094.75 06/05/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832804481
Principal investigator 1 Novo Nordisk AS $23.06 06/02/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240371
Principal investigator 1 Novo Nordisk AS $4,068.58 05/28/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823161
Principal investigator 1 Novo Nordisk AS $29,445.12 05/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811534659
Principal investigator 1 Amgen Inc. $2,328.00 05/25/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC - HF No dispute reported 06/30/2026 830981947
Principal investigator 1 Kowa Research Institute, Inc. $2,460.60 05/25/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771711402
Principal investigator 1 Janssen Research & Development, LLC $81,905.00 05/24/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839868
Principal investigator 1 SANOFI PASTEUR INC. $2,400.00 05/24/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838375837
Principal investigator 1 PFIZER INC. $847.80 05/21/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832749425
Principal investigator 1 Gilead Sciences, Inc. $746.00 05/19/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 803524469
Principal investigator 1 Novo Nordisk AS $23.06 05/19/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532123
Principal investigator 1 Janssen Research & Development, LLC $66,385.00 05/14/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839853
Principal investigator 1 Novo Nordisk AS $219.00 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189087
Principal investigator 1 Novo Nordisk AS $36.00 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189097
Principal investigator 1 Novo Nordisk AS $1.50 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189107
Principal investigator 1 Novo Nordisk AS $4.87 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189117
Principal investigator 1 Novo Nordisk AS $20.00 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502249
Principal investigator 1 Novo Nordisk AS $4.00 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502315
Principal investigator 1 Novo Nordisk AS $0.10 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818845
Principal investigator 1 Novo Nordisk AS $162.90 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818847
Principal investigator 1 Novo Nordisk AS $594.00 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818849
Principal investigator 1 Novo Nordisk AS $2.65 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818851
Principal investigator 1 Novo Nordisk AS $2.86 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849123
Principal investigator 1 Novo Nordisk AS $1.51 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849125
Principal investigator 1 Novo Nordisk AS $19.95 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849127
Principal investigator 1 Novo Nordisk AS $3.25 05/07/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849129
Principal investigator 1 PFIZER INC. $9,073.45 05/07/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832738275
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189057
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189067
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189077
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189127
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189221
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189529
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189539
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189549
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189559
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189569
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502259
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502269
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502275
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502285
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502295
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502305
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502325
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502335
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502411
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502573
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502583
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502593
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502603
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502613
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818835
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818837
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818839
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818841
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818843
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818853
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819003
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819005
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819007
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819009
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819011
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819013
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849119
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849121
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849155
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849157
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849159
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849161
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849189
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849191
Principal investigator 1 Novo Nordisk AS $19.96 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849193
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849195
Principal investigator 1 Novo Nordisk AS $6.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849197
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849199
Principal investigator 1 Novo Nordisk AS $100.00 05/05/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849201
Principal investigator 1 Kowa Research Institute, Inc. $1,237.50 04/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771711400
Principal investigator 1 Novo Nordisk AS $4,992.22 04/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823159
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,189.00 04/23/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 826472229
Principal investigator 1 Janssen Research & Development, LLC $315,453.00 04/23/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839839
Principal investigator 1 Novo Nordisk AS $500.00 04/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188611
Principal investigator 1 Novo Nordisk AS $3,400.00 04/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189819
Principal investigator 1 Novo Nordisk AS $600.00 04/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502653
Principal investigator 1 Novo Nordisk AS $1,200.00 04/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819027
Principal investigator 1 PFIZER INC. $226.24 04/12/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832909675
Principal investigator 1 Janssen Research & Development, LLC $56,200.00 04/09/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839825
Principal investigator 1 Novo Nordisk AS $29.90 04/02/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189049
Principal investigator 1 Novo Nordisk AS $23.06 03/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811857717
Principal investigator 1 Janssen Research & Development, LLC $18,648.00 03/24/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787839221
Principal investigator 1 Janssen Research & Development, LLC $150,420.00 03/24/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839497
Principal investigator 1 Novo Nordisk AS $3,602.27 03/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811055665
Principal investigator 1 Novo Nordisk AS $864.00 03/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240983
Principal investigator 1 Novo Nordisk AS $250.00 03/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811823157
Principal investigator 1 PFIZER INC. $13,000.00 03/24/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 832867119
Principal investigator 1 Kowa Research Institute, Inc. $3,222.90 03/22/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771712298
Principal investigator 1 Gilead Sciences, Inc. $811.00 03/17/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 803524467
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 03/17/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787839207
Principal investigator 1 Janssen Research & Development, LLC $6,400.00 03/17/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839483
Principal investigator 1 Novo Nordisk AS $562.00 03/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502161
Principal investigator 1 Novo Nordisk AS $1,970.00 03/16/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502169
Principal investigator 1 PFIZER INC. $2,500.00 03/05/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832827041
Principal investigator 1 SANOFI PASTEUR INC. $1,925.00 03/05/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838375775
Principal investigator 1 SANOFI PASTEUR INC. $21,585.00 03/03/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838375799
Principal investigator 1 Kowa Research Institute, Inc. $2,460.60 03/01/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771712296
Principal investigator 1 Novo Nordisk AS $250.00 02/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240675
Principal investigator 1 Novo Nordisk AS $400.00 02/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314281
Principal investigator 1 Novo Nordisk AS $0.20 02/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189519
Principal investigator 1 Novo Nordisk AS $5.72 02/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502239
Principal investigator 1 Novo Nordisk AS $325.80 02/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818833
Principal investigator 1 Novo Nordisk AS $438.00 02/25/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849117
Principal investigator 1 Novo Nordisk AS $790.56 02/24/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240655
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188621
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188631
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188641
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188651
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188661
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188669
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188679
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811188689
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189153
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189163
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189173
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189183
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189193
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189203
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189213
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189443
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189453
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189461
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189469
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189479
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189489
Principal investigator 1 Novo Nordisk AS $9.74 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189499
Principal investigator 1 Novo Nordisk AS $40.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811189509
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502179
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502189
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502199
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502209
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502219
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502229
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502391
Principal investigator 1 Novo Nordisk AS $5.30 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502401
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502451
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502459
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502467
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502477
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502487
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502497
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502507
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502517
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502523
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502533
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502547
Principal investigator 1 Novo Nordisk AS $72.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502554
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811502563
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818773
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818775
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818777
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818779
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818781
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818819
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818821
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818823
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818825
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818827
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818829
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818831
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818899
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818901
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818903
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818905
Principal investigator 1 Novo Nordisk AS $3.02 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818907
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818913
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818915
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818917
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818919
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818921
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818923
Principal investigator 1 Novo Nordisk AS $8.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818925
Principal investigator 1 Novo Nordisk AS $39.90 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811818999
Principal investigator 1 Novo Nordisk AS $6.50 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811819001
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849089
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849091
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849093
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849095
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849097
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849099
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849101
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849103
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849105
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849107
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849109
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849111
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849113
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849115
Principal investigator 1 Novo Nordisk AS $18.25 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849147
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849149
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849151
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849153
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849171
Principal investigator 1 Novo Nordisk AS $3.05 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849173
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849175
Principal investigator 1 Novo Nordisk AS $1.95 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849177
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849179
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849181
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849183
Principal investigator 1 Novo Nordisk AS $9.98 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849185
Principal investigator 1 Novo Nordisk AS $3.00 02/23/2021 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH, INC
NN1436-4478 No dispute reported 06/30/2026 811849187
Principal investigator 1 Janssen Research & Development, LLC $253,135.00 02/22/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839469
Principal investigator 1 Novo Nordisk AS $4,692.40 02/22/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811314271
Principal investigator 1 Janssen Research & Development, LLC $6,400.00 02/19/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839455
Principal investigator 1 Novo Nordisk AS $23.06 02/17/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532113
Principal investigator 1 Novo Nordisk AS $23.06 02/12/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811532103
Principal investigator 1 Novo Nordisk AS $8,511.24 01/28/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811780835
Principal investigator 1 Janssen Research & Development, LLC $382,004.00 01/26/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839437
Principal investigator 1 Kowa Research Institute, Inc. $6,283.80 01/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 771712294
Principal investigator 1 Novo Nordisk AS $790.56 01/26/2021 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 811240361
Principal investigator 1 PFIZER INC. $110.89 01/20/2021 Non-covered Recipient Entity
Buynak Clinical Research
A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE No dispute reported 06/30/2026 832809595
Principal investigator 1 SANOFI PASTEUR INC. $11,325.00 01/19/2021 Non-covered Recipient Entity
Velocity Clinical Research Inc
PSK00009 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years No dispute reported 06/30/2026 838375735
Principal investigator 1 Janssen Research & Development, LLC $10,970.00 01/07/2021 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787839425
Principal investigator 1 GlaxoSmithKline, LLC. $156.00 01/03/2021 Non-covered Recipient Entity
PHARMASEEK LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 809492157
Principal investigator 1 GlaxoSmithKline, LLC. $1,034.80 01/03/2021 Non-covered Recipient Entity
PHARMASEEK LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 809492159
Principal investigator 1 GlaxoSmithKline, LLC. $130.00 01/03/2021 Non-covered Recipient Entity
PHARMASEEK LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 809508637